NCT05142020 is a clinical trial in Gestatiaonl Diabetes Mellitus, sponsored by Women's Hospital School Of Medicine Zhejiang University.

Who is sponsoring NCT05142020?

NCT05142020 is sponsored by Women's Hospital School Of Medicine Zhejiang University.

What condition does NCT05142020 study?

NCT05142020 studies Gestatiaonl Diabetes Mellitus, Early Pregnancy.

Is NCT05142020 still recruiting?

NCT05142020 is currently status unknown. Last updated 1 February 2023.

Last reviewed 2023-02-01 · How we verify

NCT05142020

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Biomarkers for Early Screening of Gestational Diabetes Mellitus

Status unknown Last updated 1 February 2023

What this trial tests

trial in Gestatiaonl Diabetes Mellitus in 480 participants. Status unknown.

Timeline

1 January 2022

Primary endpoint
22 August 2022

31 December 2023

Quick facts

Lead sponsor	Women's Hospital School Of Medicine Zhejiang University
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	480
Start date	1 January 2022
Primary completion	22 August 2022
Estimated completion	31 December 2023
Sites	1 location across China

Conditions studied

Gestatiaonl Diabetes Mellitus — all drugs for Gestatiaonl Diabetes Mellitus →
Early Pregnancy — all drugs for Early Pregnancy →

Sponsor

Women's Hospital School Of Medicine Zhejiang University

Who can join

Adults 20 to 49, female only, with Gestatiaonl Diabetes Mellitus or Early Pregnancy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Gestational Diabetes Mellitus (GDM) refers to the abnormal glucose metabolism first detected during pregnancy. It is estimated that approximately 7% of pregnant women worldwide and their offspring are affected by GDM. The incidence of GDM in China is as high as 18.9%. A number of studies have shown that GDM complicates 3%-25% of pregnancies and poses serious health and life threats to the mother and child. In fact, due to the lack of physical activity during pregnancy and the decrease of insulin sensitivity compared with non-pregnancy, the optimal time for intervention has long been lost until the diagnosis of GDM in the second trimester. However, it is a pity that no authoritative screening method for GDM in early pregnancy has been established, and the pathogenesis of GDM is still unclear. This study intend to search for biomarkers used for screening of GDM in early pregnancy and explore the pathogenesis of GDM, so as to provide new ideas for prevention measures and treatment targets of GDM.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Gestatiaonl Diabetes Mellitus

Currently open trials in the same condition.

NCT07161947 — Shanghai Clinical Cohort of Hyperglycemia in Pregnancy · recruiting
NCT07125885 — Gongji Pregnancy Endorine Cohort Study · recruiting

Other Women's Hospital School Of Medicine Zhejiang University trials

Trials by the same sponsor.

NCT07369986 — Immunotherapy for Surgery Avoidance in Vulnerable dMMR Endometrial Cancer · Phase 2 · not yet recruiting
NCT07244965 — Neoadjuvant Ivonescimab Plus Chemotherapy Followed by Concurrent Chemoradiotherapy in High-Risk Locally Advanced Cervica · Phase 2 · not yet recruiting
NCT06561308 — Clinical Efficacy Study of PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Advanced Endometrial Cancer · Phase 2 · recruiting
NCT07106853 — Prenatal Cell-free DNA Screening in Pregnancies With Diverse Genetic Risk Profiles Utilizing Targeted and Whole-exome Se · not yet recruiting
NCT07082530 — A RCT of Labor Induction at 39 Weeks in Low - Risk Women in China · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05142020 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Women's Hospital School Of Medicine Zhejiang University
Last refreshed: 1 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05142020.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing